Premium
Is Flecainide Dangerous in Long QT‐3 Patients?
Author(s) -
BEINART ROY,
MICHAILIDIS ATHANASIOS,
GUREVITZ OSNAT T.,
GLIKSON MICHAEL
Publication year - 2009
Publication title -
pacing and clinical electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 101
eISSN - 1540-8159
pISSN - 0147-8389
DOI - 10.1111/j.1540-8159.2009.02190.x
Subject(s) - flecainide , medicine , brugada syndrome , long qt syndrome , qt interval , cardiology , short qt syndrome , sodium channel blocker , sodium channel , sodium , atrial fibrillation , chemistry , organic chemistry
Mutations of the cardiac sodium channel gene, SCN5A, are present in both long‐QT and Brugada syndromes. Flecainide is used as a provocative test to unmask the electrocardiogram (ECG) phenotype of the Brugada syndrome, as well as long‐term treatment for long QT‐3 syndrome, since it shortens the QT interval. We report a case where oral flecainide induced syncope with a Brugada ECG pattern in a patient with known long QT‐3 syndrome.